Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
View in:
PubMed
subject areas
Administration, Oral
Adult
Aged
Anemia
Antineoplastic Agents
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
Neutropenia
Quinazolines
Thrombocytopenia
authors with profiles
Mark J. Ratain
Richard Schilsky
Gini Fleming